Coherus' LOQTORZI Enters Phase 1 Combination Trial for Multiple Cancers
CHRS has more than doubled off its 52-week low of $0.71 on light trading volume (0.3× avg).
Summary
Coherus Oncology announced a clinical collaboration with Zumutor Biologics to evaluate its approved drug LOQTORZI in a Phase 1 combination trial with Zumutor's ZM008. The trial, which has already dosed its first patient, aims to expand LOQTORZI's potential indications into multiple solid tumors including colorectal, head and neck, and lung cancers. This strategic partnership allows Coherus to cost-efficiently explore new, larger markets for its key oncology product, building on the strong LOQTORZI revenue reported in Q1 2026.
At the time of this announcement, CHRS was trading at $1.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $229.1M. The 52-week trading range was $0.71 to $2.62. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.